Literature DB >> 26336106

Combination of Correctors Rescue ΔF508-CFTR by Reducing Its Association with Hsp40 and Hsp27.

Miquéias Lopes-Pacheco1, Clément Boinot2, Inna Sabirzhanova2, Marcelo M Morales3, William B Guggino2, Liudmila Cebotaru4.   

Abstract

Correcting the processing of ΔF508-CFTR, the most common mutation in cystic fibrosis, is the major goal in the development of new therapies for this disease. Here, we determined whether ΔF508 could be rescued by a combination of small-molecule correctors, and identified the mechanism by which correctors rescue the trafficking mutant of cystic fibrosis transmembrane conductance regulator (CFTR). We transfected COS-7 cells with ΔF508, created HEK-293 stably expressing ΔF508, and utilized CFBE41o(-) cell lines stably transduced with ΔF508. As shown previously, ΔF508 expressed less protein, was unstable at physiological temperature, and rapidly degraded. When the cells were treated with the combination C18 + C4 the mature C-band was expressed at the cell surface. After treatment with C18 + C4, we saw a lower rate of protein disappearance after translation was stopped with cycloheximide. To understand how this rescue occurs, we evaluated the change in the binding of proteins involved in endoplasmic reticulum-associated degradation, such as Hsp27 (HspB1) and Hsp40 (DnaJ). We saw a dramatic reduction in binding to heat shock proteins 27 and 40 following combined corrector therapy. siRNA experiments confirmed that a reduction in Hsp27 or Hsp40 rescued CFTR in the ΔF508 mutant, but the rescue was not additive or synergistic with C4 + 18 treatment, indicating these correctors shared a common pathway for rescue involving a network of endoplasmic reticulum-associated degradation proteins.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  ABC transporter; chaperonin; electrophysiology; heat shock protein (HSP); lung; membrane; mutant; protein degradation; protein folding; protein processing

Mesh:

Substances:

Year:  2015        PMID: 26336106      PMCID: PMC4646207          DOI: 10.1074/jbc.M115.671925

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis.

Authors:  S H Cheng; R J Gregory; J Marshall; S Paul; D W Souza; G A White; C R O'Riordan; A E Smith
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

Review 2.  Molecular chaperone functions in protein folding and proteostasis.

Authors:  Yujin E Kim; Mark S Hipp; Andreas Bracher; Manajit Hayer-Hartl; F Ulrich Hartl
Journal:  Annu Rev Biochem       Date:  2013       Impact factor: 23.643

3.  Cystic fibrosis transmembrane regulator missing the first four transmembrane segments increases wild type and DeltaF508 processing.

Authors:  Liudmila Cebotaru; Neeraj Vij; Igor Ciobanu; Jerry Wright; Terence Flotte; William B Guggino
Journal:  J Biol Chem       Date:  2008-05-28       Impact factor: 5.157

Review 4.  Cystic fibrosis: a disease in electrolyte transport.

Authors:  P M Quinton
Journal:  FASEB J       Date:  1990-07       Impact factor: 5.191

5.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

6.  Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator.

Authors:  Hal A Lewis; Sean G Buchanan; Stephen K Burley; Kris Conners; Mark Dickey; Michael Dorwart; Richard Fowler; Xia Gao; William B Guggino; Wayne A Hendrickson; John F Hunt; Margaret C Kearins; Don Lorimer; Peter C Maloney; Kai W Post; Kanagalaghatta R Rajashankar; Marc E Rutter; J Michael Sauder; Stephanie Shriver; Patrick H Thibodeau; Philip J Thomas; Marie Zhang; Xun Zhao; Spencer Emtage
Journal:  EMBO J       Date:  2003-12-18       Impact factor: 11.598

7.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.

Authors:  Fredrick Van Goor; Sabine Hadida; Peter D J Grootenhuis; Bill Burton; Dong Cao; Tim Neuberger; Amanda Turnbull; Ashvani Singh; John Joubran; Anna Hazlewood; Jinglan Zhou; Jason McCartney; Vijayalaksmi Arumugam; Caroline Decker; Jennifer Yang; Chris Young; Eric R Olson; Jeffery J Wine; Raymond A Frizzell; Melissa Ashlock; Paul Negulescu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-21       Impact factor: 11.205

Review 8.  CFTR and chaperones: processing and degradation.

Authors:  Margarida D Amaral
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 9.  CFTR function and prospects for therapy.

Authors:  John R Riordan
Journal:  Annu Rev Biochem       Date:  2008       Impact factor: 23.643

10.  Correcting the cystic fibrosis disease mutant, A455E CFTR.

Authors:  Liudmila Cebotaru; Daniele Rapino; Valeriu Cebotaru; William B Guggino
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

View more
  23 in total

1.  The CFTR Corrector, VX-809 (Lumacaftor), Rescues ABCA4 Trafficking Mutants: a Potential Treatment for Stargardt Disease.

Authors:  Qiangni Liu; Inna Sabirzhanova; Emily Anne Smith Bergbower; Murali Yanda; William G Guggino; Liudmila Cebotaru
Journal:  Cell Physiol Biochem       Date:  2019

2.  A new role for heat shock factor 27 in the pathophysiology of Clostridium difficile toxin B.

Authors:  Murali K Yanda; William B Guggino; Liudmila Cebotaru
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-11-11       Impact factor: 4.052

3.  Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.

Authors:  Liudmila Cebotaru; Qiangni Liu; Murali K Yanda; Clement Boinot; Patricia Outeda; David L Huso; Terry Watnick; William B Guggino; Valeriu Cebotaru
Journal:  Kidney Int       Date:  2016-03-25       Impact factor: 10.612

4.  Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease.

Authors:  Murali K Yanda; Boyoung Cha; Cristina V Cebotaru; Liudmila Cebotaru
Journal:  J Biol Chem       Date:  2019-09-30       Impact factor: 5.157

5.  A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease.

Authors:  Darren M Hutt; Salvatore Loguercio; Alexandre Rosa Campos; William E Balch
Journal:  J Mol Biol       Date:  2018-06-18       Impact factor: 5.469

6.  A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector.

Authors:  Murali K Yanda; Qiangni Liu; Liudmila Cebotaru
Journal:  J Biol Chem       Date:  2018-06-06       Impact factor: 5.157

7.  Correctors Rescue CFTR Mutations in Nucleotide-Binding Domain 1 (NBD1) by Modulating Proteostasis.

Authors:  Miquéias Lopes-Pacheco; Inna Sabirzhanova; Daniele Rapino; Marcelo M Morales; William B Guggino; Liudmila Cebotaru
Journal:  Chembiochem       Date:  2016-02-16       Impact factor: 3.164

8.  The Mitochondrial Ca2+ import complex is altered in ADPKD.

Authors:  Murali K Yanda; Vartika Tomar; Robert Cole; William B Guggino; Liudmila Cebotaru
Journal:  Cell Calcium       Date:  2021-11-19       Impact factor: 6.817

9.  Transduction of Surface and Basal Cells in Rhesus Macaque Lung Following Repeat Dosing with AAV1CFTR.

Authors:  William B Guggino; Murali K Yanda; Cristina V Cebotaru; Liudmila Cebotaru
Journal:  Hum Gene Ther       Date:  2020-09       Impact factor: 5.695

10.  Rescue of CFTR NBD2 mutants N1303K and S1235R is influenced by the functioning of the autophagosome.

Authors:  Qiangni Liu; Inna Sabirzhanova; Murali K Yanda; Emily A S Bergbower; Clément Boinot; William B Guggino; Liudmila Cebotaru
Journal:  J Cyst Fibros       Date:  2018-06-20       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.